INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease

Siemers, E., Feaster, T., Sethuraman, G., Sundell, K., Skljarevski, V., Cline, E. N., Zhang, H., Jerecic, J., Honig, L. S., Salloway, S., Sperling, R., Trame, M. N., Dodds, M. G., & Johnson, K. (2025). INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The Journal of Prevention of Alzheimer’s Disease, 12(1), 100005. https://doi.org/10.1016/j.tjpad.2024.100005

Authors:

Eric Siemers

Todd Feaster

Gopalan Sethuraman

Karen Sundell

Vladimir Skljarevski

Erika N. Cline

Hao Zhang

Jasna Jerecı̀ć

Lawrence S. Honig

Stephen Salloway

Reisa A. Sperling